Brief: Cabaletta Bio And Wuxi Advanced Therapies Announce Expansion Of Gmp Manufacturing Agreement To Include Caba-201

Cabaletta Bio

22/08/2023 13:06

Aug 22 (Reuters) - 
  
    * CABALETTA BIO AND WUXI ADVANCED THERAPIES ANNOUNCE
EXPANSION OF
GMP MANUFACTURING AGREEMENT TO INCLUDE CABA-201
    * CABALETTA BIO INC - AGREEMENT EXPANSION FACILITATES
PREPARATION
FOR COMMERCIAL READINESS FOR CABA-201
    * CABALETTA BIO INC - UNDER TERMS OF AGREEMENT, WUXI ATU
WILL
PROVIDE GMP MANUFACTURING OF CABA-201
    * CABALETTA BIO INC - WUXI ATU WILL CONTINUE TO SERVE AS
CO'S CELL
PROCESSING MANUFACTURING PARTNER FOR MUSCAARTES PHASE 1 CLINICAL
TRIAL OF MUSK-CAART

Source text for Eikon:  ID:nGNX8mKpt2 
Further company coverage:  CABA.O 

 ((reuters.briefs@thomsonreuters.com;))